Grove Biopharma to Participate in Materials Biology Symposium at ACS Fall 2025 Scientific Meeting
Grove Biopharma, a private biotechnology company pioneering its Bionic Biologics™ platform to develop therapies targeting previously intractable intracellular disease targets, announced today it will present an update at the annual American Chemical Society (ACS) Fall meeting being held August 17-21, 2025, in Washington D.C.
Grove Biopharma Closes $30 Million Series A Financing to Advance Bionic Biologics™, a New Therapeutic Modality
Grove Biopharma, a private biotechnology company pioneering its Bionic Biologics™ platform to develop therapies targeting previously intractable intracellular disease targets, today announced the close of a $30 million Series A financing. The round was led by DCVC Bio with participation from Eli Lilly and Company, InVivium Capital, Walder Ventures, Gradiant Corporation, Mansueto Investments, and others. They join existing seed supporters, including Portal Innovations, where Grove was incubated. Proceeds will be used to further advance Grove Biopharma’s proprietary platform and drive its lead oncology programs towards the clinic.
